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Abstract: BACKGROUND Left atrial appendage occlusion (LAAO) represents a treatment alternative
to anticoagulation in patients with atrial fibrillation. We evaluate a novel device for epicardial LAAO
in a translational canine model. METHODS Nine hounds (n = 9) were used to assess usability, safety,
and efficacy of the TigerPaw Pro (TPP) device for epicardial LAAO. Following baseline imaging (intra-
cardiac echocardiography (ICE) and angiography) and intraoperative visual inspection, usability was
tested via a “closure/re-opening“ maneuver followed by deployment of a total of twenty TPP devices (n
= 20) on the left and right atrial appendages respectively. Procedural safety was evaluated by assessing
for adverse-events via direct Epicardial inspection and endocardial imaging. Efficacy evaluation included
assessment of device positioning, presence of residual stumps and completeness of closure. Post-mortem
evaluation was performed to confirm safety and efficacy. RESULTS Usability testing of all TPP devices
was successful (n = 20;100%, delivery-time range 22-120 s) without any procedural adverse-events (tissue
damage or tears, bleeding, vessel-impingement, structural impact). All devices fully traversed the ostium
(n = 18) or appendage body (n = 2), and conformed smoothly to adjacent cardiac anatomy. In nineteen
deployments (n = 19;95%), all device connector pairs were fully engaged, while in one TPP device the
most distal pair remained unengaged. ICE and post-mortem inspections revealed complete closure of all
appendage ostia (n = 18;100%) and only in one case a small residual stump was detected. Intraoperative
safety findings were further confirmed post-mortem. Devices created a nearly smooth line of closure via
symmetric endocardial tissue-coaptation. CONCLUSIONS In this preclinical model, the TPP demon-
strated good ease of use for ostial access, ability to re-position (after engagement) and rapid deployment,
while achieving safe and effective LAAO.
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Abstract
Background: Left atrial appendage occlusion (LAAO) represents a treatment alternative to anticoagulation in
patients with atrial fibrillation. We evaluate a novel device for epicardial LAAO in a translational canine model.
Methods: Nine hounds (n = 9) were used to assess usability, safety, and efficacy of the TigerPaw Pro (TPP) device
for epicardial LAAO. Following baseline imaging (intra-cardiac echocardiography (ICE) and angiography) and
intraoperative visual inspection, usability was tested via a ``closure/re-opening`` maneuver followed by deployment
of a total of twenty TPP devices (n = 20) on the left and right atrial appendages respectively. Procedural safety was
evaluated by assessing for adverse-events via direct Epicardial inspection and endocardial imaging. Efficacy
evaluation included assessment of device positioning, presence of residual stumps and completeness of closure.
Post-mortem evaluation was performed to confirm safety and efficacy.
Results: Usability testing of all TPP devices was successful (n = 20;100%, delivery-time range 22–120 s) without any
procedural adverse-events (tissue damage or tears, bleeding, vessel-impingement, structural impact). All devices
fully traversed the ostium (n = 18) or appendage body (n = 2), and conformed smoothly to adjacent cardiac
anatomy. In nineteen deployments (n = 19;95%), all device connector pairs were fully engaged, while in one TPP
device the most distal pair remained unengaged. ICE and post-mortem inspections revealed complete closure of all
appendage ostia (n = 18;100%) and only in one case a small residual stump was detected. Intraoperative safety
findings were further confirmed post-mortem. Devices created a nearly smooth line of closure via symmetric
endocardial tissue-coaptation.
Conclusions: In this preclinical model, the TPP demonstrated good ease of use for ostial access, ability to re-
position (after engagement) and rapid deployment, while achieving safe and effective LAAO.
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Background
Atrial fibrillation (AF) is an independent risk factor for
stroke and systemic embolism [1]. Randomized con-
trolled trials (RCTs) have shown oral anticoagulation
(OAC) to be effective in the prevention of stroke [2]. As
such, vitamin K antagonists (VKAs) have remained the
gold-standard treatment for decades. Newer non-vitamin
K dependent oral anticoagulants (NOACs) with im-
proved safety and efficacy profiles have lately replaced
VKAs as the first-line treatment option [3]. However,
the risk of serious bleeding events inherent for all anti-
thrombotic agents requires the development of alterna-
tive stroke prevention strategies for patients with AF.
Mechanical exclusion of the LAA, the site of predilec-
tion, has been suggested and is currently under investi-
gation [4]. Various surgical exclusion techniques have
evolved over the decades. Device-enabled techniques
(e.g. surgical stapler devices) replenished these develop-
ments; however, none of these achieved reliable and
complete closure of the LAA and data on these tech-
niques were mostly inconclusive in their results [4]. The
development of percutaneous catheter-based techniques
emerged as another promising alternative strategy [5, 6],
with robust clinical data. However, due to several limita-
tions (e.g. presence of device-related thrombi, periproce-
dural complications and residual LAA peri-device leaks)
with still-unknown clinical implications, the need for al-
ternative surgical approaches with compelling clinical
evidence still exists [4]. The development of new epicar-
dial surgical devices with promising initial clinical results
was intended to address this void. First, the AtriClip
(AtriCure, Inc.) LAA exclusion system was introduced in
2007 and Initial experience showed an excellent safety,
efficacy and durability profile [7] which was further con-
firmed by imaging-controlled mid- and long-term
follow-up results [8, 9].
Another device, the TigerPaw System II (LAAx, Inc.,
Livermore, CA, now Getinge AB, Sweden) —consisting
of an implantable LAA tissue fastener and accompanying
delivery tool — was introduced into clinical practice in
2011 following a clinical trial in 2009 [10]. Results from
this prospective, multicenter trial [10] demonstrated fa-
vorable outcomes - comparable to AtriClip - of this
LAA exclusion device. However, despite these encour-
aging initial data for the TigerPaw System II, the device
underwent an FDA Class I recall voluntarily initiated by
Maquet, Getinge Group in 2015 due to increased field
complaints for incomplete closure of the TigerPaw Sys-
tem II Fastener that may result in tissue tears and/or
bleeding [11] . In order to address the intra-procedural
issues and to reintroduce the device into clinical use,
TigerPaw has undergone systemic re-engineering and re-
development into a next-generation design, the Tiger-
Paw Pro (TPP) device. In this study, the redesigned TPP
for epicardial LAAO was evaluated for procedural feasi-
bility, safety, success and usability in a translational ca-
nine model.
Methods
Study design and animals
This is the first preclinical study to evaluate the novel
TigerPaw Pro (TPP) device for epicardial LAA closure in
an in vivo, open chest, beating-heart hound model. All
procedures were conducted at Preclinical Medevice In-
novations (San Carlos, CA, USA), a USDA−/NIH
−/FDA-registered and AAALAC-accredited facility. The
study was approved by the test facility Institutional Ani-
mal Care and Use Committee (IACUC ANS 2156, non-
GLP; IACUC ANS 2312, GLP), and was conducted per
their standard operating procedures. Overall, nine (n =
9) hounds were used. Three animals were used for train-
ing the study personnel. Procedures on the other six ani-
mals were conducted according to the US FDA 21 C.F.R.
§58 Good Laboratory Practice for Nonclinical Labora-
tory Studies (GLP). The non-GLP training procedures
(n = 3) and GLP procedures (n = 6) were assessed in an
identical manner, hence, data from all animals were
pooled and presented together.
TigerPaw pro (TPP) device
The TPP device is a mechanical system for surgical oc-
clusion of the LAA during open heart procedures under
direct visualization. TPP consists of a flexible implant-
able tissue clamp (fastener) that is pre-loaded onto a dis-
posable delivery instrument (delivery tool) for
deployment at the LAA ostium. The fastener is based on
the principle of pledgeted interrupted mattress sutures,
using linearly spaced opposing connector pairs to close
the LAA ostium. Each connector pair consists of a male
pin that, when deployed via the delivery tool, pierces
through tissue to lock into the opposing female segment.
Connector engagement is permanent, for secure, durable
closure of the LAA ostium, and to mitigate the risk of
implant migration. The rigid connector pairs are
enclosed within and joined together by a soft, compliant
silicone housing, which forms an atraumatic exterior to
the fastener, to minimize the risk of abrasion or erosion
of adjacent tissues. In addition, the soft silicone housing
between connector pairs allows the fastener to flex and
conform to the morphology of the appendage ostium
and adjacent atrium. Following the market withdrawal of
TigerPaw System II, the delivery tool was substantially
re-engineered to address the intra-procedural perform-
ance issues that led to the recall: first, he device jaws can
now be reopened and repositioned prior to initiating fas-
tener deployment and the reliability of the fastener de-
ployment mechanism was greatly improved. In brief, the
new fastener design replaces the sharp point barbs with
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blunt bars that have a definitive trial stop location. This
design is based on friable tissue suture needles thereby
reducing the likelihood of tissue tear or bleeding. Add-
itional design changes that reduce the likelihood for
tearing include the single handle design and yellow trig-
ger mechanism, which aid in preventing movement of
the deployment mechanism when placing the fastener.
Next, small changes to the design, such as changing
plastic components to metal, increase the robustness of
the mechanism to place the fastener without movement.
Taken together, the overall design was refined to reduce
the risk of tissue tears or inadvertent puncture, while the
delivery tool was redesigned to improve ergonomics.
However, the fastener implant is largely unchanged
from the previous generation, which had an unremark-
able safety history post-implantation, and thus is not the
focus of this study. The device has two sizes of fastener:
35 mm and 45mm working length (with seven and nine
connector pairs respectively) (Fig. 1).
Test devices
A total of twenty-one devices (45 mm;n = 14 and 35mm;
n = 7) were used to conduct the in vivo evaluations
(Table 1). Of these, twenty devices (n = 20) were de-
ployed, while one TPP device (35 mm) was not deployed
and intra-operatively exchanged with a larger device
(45 mm). All test devices consisted of pre-commercial
units, but were representative of the commercial TPP
design, manufacture, assembly, and processing.
Anesthesia, preoperative procedures, surgical access and
baseline imaging
The canine model was selected due to its similarities to
humans with respect to cardiac-size and morphology.
Furthermore, the narrow, deep thoracic cavity of the
model can present a challenging geometry for access
and device placement, to enhance the rigor of the evalu-
ation. Animal ages ranged from 6.5-11 months (18.6–
30.7 kg). Prior to the study, all animals were assessed to
Fig. 1 TigerPaw Pro delivery instrument (delivery tool) and flexible implantable tissue clamp (fastener). The fastener is supplied pre-loaded onto
the delivery tool jaws as shown. Inset image shows a magnified view of the 45 mm working length fastener, consisting of nine rigid opposing
male-female connector pairs enclosed and joined by a soft, compliant housing
Table 1 Number of TPP fasteners deployed
Location of
deployment
Number of fasteners deployed
45mm 35mm
LAA ostium/neck 9
RAA ostium/neck 5 4a
LAA body – 1
RAA body 1
aOne additional 35 mm device was not deployed and intra-operatively
replaced with 45mm device after initial positioning
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be suitable, with no abnormalities noted during a veter-
inary examination.
Study animals were prepared per standard veterinary
procedures for cardiac surgery. Following intubation and
start of anesthesia, animals were placed in dorsal recum-
bency and intermittent positive pressure ventilation was
initiated. Monitoring was established for blood pressure,
temperature, heart rate, respiratory rate, airway gases,
body position, percent oxygen saturation, electrocardio-
gram, and activated clotting time (ACT). Animals were
administered Ringer’s lactate solution via intravenous drip.
Lidocaine and/or phenylephrine were administered as
needed for visceral analgesia and hypotension. Blood was
drawn for complete blood count and serum chemistry.
After assessment of the activated clotting time (ACT),
a midline incision was made from the region of the thor-
acic inlet to the caudal aspect of the rib cage. A sternal
saw (Stryker, Kalamazoo, MI, USA) was used to open
the thoracic cavity. The pericardium was opened to ex-
pose the heart, the right atrial appendage (RAA), and the
LAA; next, the pericardium was sutured to the body wall
to create a “pericardial cradle”. Following sternotomy
procedures, heparin was administered at a dosage deter-
mined by the anesthesiologist to maintain an ACT of
≥250 s. ACT (Accriva Diagnostics, San Diego, CA, USA)
was monitored every 15-30 min thereafter.
Baseline imagery was obtained using intra-cardiac echo-
cardiography (ICE) (Vivid iq console (GE Healthcare,
Chicago, IL, USA); Acunav catheter (Siemens Medical So-
lutions, Mountain View, CA, USA) and angiography (GE
OEC 9800 Plus C-Arm and workstation (GE Healthcare);
Cordis diagnostic catheter (Cardinal Health, Dublin, OH,
USA); guidewire (Merit Medical Systems, South Jordan,
UT, USA); OptiRay contrast (Guerbet, Bloomington, IN,
USA) to assess cardiac morphology including LA and
LAA ostium, mitral-valve function, left-ventricular func-
tion, and the left coronary-system including the left anter-
ior descending (LAD) and circumflex (CX) arteries.
Device assessment
Epicardial evaluation and device testing protocol
The LAA was examined to determine the suitability for
TPP application, before it was prepared per the manu-
facturer’s instructions. Before entering the thoracic
space, ACT of ≥250 s was confirmed (for enhanced abil-
ity to detect bleeding in the event of device-related tissue
injury). The LAA appendage was accessed with the de-
livery tool (with the pre-loaded fastener) and jaw orien-
tation was adjusted using the rotation knob as needed
for an optimal access angle. The device was positioned
with the LAA seated as close as possible to the proximal
end/elbow of the fastener. Feasibility and usability of a
``closure and re-opening`` maneuver was tested by
clamping (closing) the delivery tool jaws on the LAA
tissue without initiating fastener deployment, then
reopening the jaws (with attached fastener) and remov-
ing them from the LAA ostium. Immediately after re-
moval, the site of closure was carefully inspected for
potential tissue impact or injury (e.g., tissue damage,
tears, bleeding). The inspection was repeated ≥5 min
after jaw removal, in case of late or delated adverse-
events. All jaw closures for this maneuvers were located
on the body of the LAA, away from the neck/ostium so
as not to confound the subsequent fastener deployment
test.
Next, device deployment was assessed including a) de-
livery tool jaw positioning, b) jaw closure, c) activation
of fastener delivery sequence (to engage connector
pairs), and d) release of the fastener from the jaws.
The delivery tool was positioned at the LAA ostium,
seating the appendage as close as possible to the prox-
imal elbow of the fastener. The delivery tool jaws were
clamped/closed, and visibility and positioning of delivery
tool jaws and fastener at LAA target were assessed (i.e.,
ability to entirely see jaws and fastener, fastener posi-
tioned at desired location). At the operator’s discretion,
the jaws were reopened as needed to obtain suitable po-
sitioning on the LAA neck/ostium. Jaw placement was
assessed to determine if fastener length was sufficient to
fully traverse the ostium. If sufficient, the fastener was
deployed on the LAA ostium (45 mm, n = 9), and the de-
livery tool was removed from the ostium. Duration of
the positioning and deployment sequence was recorded.
Contralateral and additional applications
The jaw closure and fastener deployment evaluations
were repeated on the RAA (n = 9), to obtain additional
data regarding device use. After intraoperative visual
evaluation device size (fastener working length) was se-
lected by the operator for each individual application
(45 mm, n = 5; 35 mm, n = 4).
At the operator’s discretion, additional devices were
deployed on the body either of LAA (n = 1) or the RAA
(n = 1) using a rapid deployment maneuver consisting of
the full device actuation sequence uninterrupted by
study protocol in-process assessments, to further evalu-
ate device safety and usability. The previously delivered
devices were left in place during these maneuvers.
Post-deployment epicardial and endocardial evaluation
Immediately after fastener deployment and delivery
tool removal, the site of fastener deployment and ad-
jacent structures were visually inspected for any signs
of injury or adverse-events (e.g., tissue damage, bleed-
ing, hematoma, visible vessel impingement or other
structural impact). The assessment was repeated ≥5
min after delivery tool removal, in case of late or de-
lated adverse-events.
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In addition to visual inspection for any signs of injury
or adverse events (e.g., tissue damage, bleeding,
hematoma, visible vessel impingement or other struc-
tural impact), fastener deployment on the appendage
was systematically assessed with respect to the following
characteristics:
1) Ability to place (deploy) fastener at appendage
ostium.
2) Completeness of fastener deployment with all
connector pairs fully engaged (35 mm: seven
connectors; 45 mm: nine connectors).
3) Ability of fastener to conform to local anatomy
(geometry of adjacent tissues).
4) Sufficient length to traverse appendage ostium for
complete closure.
After deployment, ICE and angiography of the LAA
and adjacent structures were repeated to assess: 1.) De-
vice safety: by evaluation for evidence of device related
injury or adverse impact (e.g., vessel impingement; struc-
tural impact); and 2.) Device efficacy: by evaluation of
fastener positioning at the ostium (e.g., remaining
stump) and of completeness of closure (i.e., endocardial
fluid communication between atrium and appendage).
Euthanasia and post-mortem evaluation
Upon completion of the in vivo assessment procedures,
animals were administered a heparin bolus to mitigate
the occurrence of post-mortem thrombus artifact. Intra-
venous potassium chloride was then administered; car-
diac arrest was confirmed prior to conducting necropsy.
Post-mortem evaluation was conducted by a board-
certified veterinary pathologist (T.S.) in conjunction with
the operators, to assess device safety and performance.
First, a brief examination of body systems was per-
formed; then, the cardiovascular system was examined
in detail.
Epicardial examination
Epicardial assessments of the appendages and adjacent struc-
tures were repeated, evaluating for the following aspects:
1. Evidence of clinically-relevant device-related injury
or adverse impact to LAA or adjacent structures
(e.g., tissue damage, bleeding, hematoma, visible
vessel impingement or other structural impact).
2. Ability of fastener to be placed (deployed) at the
appendage ostium.
3. Ability of fastener to function across a range of
appendage tissue thicknesses (all fastener connector
pairs fully engaged).
4. Ability of fastener to conform to local anatomy/
tissue.
5. Sufficient fastener length to fully traverse
appendage ostium.
Tissue thickness estimates
Thereafter, tissue thickness was approximated using
Vernier calipers (Mitutoyo, Aurora, IL) at the initial lo-
cation of jaw closure without fastener deployment as
well as immediately adjacent to the deployed ostial fas-
tener (on both heart/atrial side and appendage side).
Endocardial examination
Finally, the endocardial surfaces of the atrium and the
appendage were assessed for:
1) Device safety: by evaluation for evidence of
clinically-relevant adverse device-related impact on
endocardial surface at the site of exclusion or at ad-
jacent tissues (e.g., tissue damage, bleeding,
hematoma, vessel impingement, thrombus forma-
tion, structural impact); and
2) Device efficacy: by evaluation for evidence of
endocardial fluid communication between atrium
and appendage (i.e., incomplete closure).
Results
Baseline pre-deployment imaging & Epicardial evaluation
All animals displayed a normal cardiac morphology and
left-ventricular ejection-fraction. The mitral valve (MV)
showed a good function with no (n = 2), trace (n = 4) or
mild (n = 3) regurgitation and angiography revealed a
normal left-coronary system with a patent LAD and CX
in all animals. Epicardial inspection of the appendages
showed normal appearance and suitability for deploy-
ment in all animals (Fig. 2a-e).
TPP device testing: appendage clamping and fastener
deployment
In all nine animals, both the LAA (n = 9) and the RAA
(n= 9) could be safely accessed and a ``closure and re-
opening`` maneuver was performed uneventfully. No tissue
injury was detectable at the site of jaw closure either immedi-
ately or 5 minutes after jaw removal (Fig. 3a-f). In one ani-
mal, further inspection of the RAA revealed a minimal
hematoma on the RAA tip (i.e., not at the site of closure)
which was not considered to be device-related, but was most
likely caused by surgical forceps during grasping maneuvers
to expose the RAA. Deployment of the fastener was unevent-
ful in all animals with delivery of twenty devices. Eighteen de-
vices were delivered to the LAA ostium and to the RAA
ostium (Fig. 4a-f). To evaluate the safety and usability of a
rapid deployment maneuver (i.e., uninterrupted device actu-
ation sequence), two additional fasteners were deployed onto
the body of the LAA and RAA.
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No procedural problems or complications such as bleed-
ing, tearing or device migration were observed. Overall dur-
ation of ostial deployments, ranged from 22 to 120 s.
In all ostial deployments (n = 18) the operators were
able to entirely inspect the position of the delivery tool
jaws and fastener with respect to the LAA or RAA neck/
ostium, and to evaluate the size of the fastener for the
ostium (i.e., sufficient fastener length to fully traverse
the ostium). Based on this intra-procedural assessment,
in four applications, the operator decided to reopen (i.e.,
unclamp) the delivery tool jaws in order to better pos-
ition the jaws on the ostium. In one application, after
positioning and jaw closure of a 35 mm fastener device
on a RAA, the operator removed and exchanged the de-
vice with a longer 45 mm fastener device prior to
deploying the fastener at the ostium. In two other de-
ployments, a slight lateral movement was necessary to
fully release the fastener from the delivery tool jaw. All
of these maneuvers could be performed quickly and un-
eventfully, demonstrating good ease of use of the device.
Post-deployment evaluations of device safety and efficacy
Post-procedural epicardial assessment confirmed suc-
cessful deployment of all fasteners (n = 20;100%) onto
the LAA ostium (n = 9), RAA ostium (n = 9), and the
LAA (n = 1) or RAA body (n = 1) without evidence of
structural impact, vessel impingement, bleeding,
hematoma or tissue damage. The deployed fasteners
curved to conform smoothly to adjacent cardiac-
anatomy without compromising any surrounding struc-
tures. The fastener length was sufficient to traverse the
entire ostium or appendage body in all cases (100%). In
nineteen deployments (95%), all fastener connector pairs
appeared to be fully engaged, while in one case using the
45mm fastener, the most distal connector pair of the
fastener (ninth of nine pairs) that was positioned beyond
the LAA tissue was not engaged. This was attributed by
the operator to unintended capture of pericardial tissue
within the jaws (fastener tips) temporarily during the po-
sitioning step of the deployment procedure, a situation
likely induced by the use of the larger 45 mm device (i.e.,
oversized relative to the target appendage) in the small
canine chest. Nevertheless, the device was able to be po-
sitioned and deployed at the ostium, and LAAO was
complete.
No evidence of tissue damage or bleeding was detected
on endocardial evaluation. Angiography displayed an un-
changed left coronary system. In 8/9 animals, ICE as-
sessment of the LAA showed complete LAAO without
any evidence of fluid communication (Fig. 5a-c).
Fig. 2 a-e Epicardial inspection and baseline (pre-deployment) imaging. Visual inspection of LAA and RAA (a and b). Left coronary angiography
(c). Intra-cardiac echocardiography of LA and LAA (d) and MV (e)
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Complete LAAO could not be confirmed in the ninth
animal, but was subsequently confirmed in necropsy, in-
dicating a good efficacy profile of the device (100%).
In eight applications (89%), no LAA stump was detect-
able, while in one animal a small residual stump was vis-
ible suggesting that the device was not exactly
positioned on the ostium. This was attributed by the op-
erator to the space constraints in the small canine chest.
In the same animal, the MV presented with moderate
regurgitation after fastener deployment (increasing from
trace regurgitation pre-deployment). However, ICE dis-
played that the regurgitation jet was central and that the
MV was structurally unremarkable, suggestive that this
finding was not related to the deployed fastener. MV
function was unchanged in the remaining eight animals,
and all nine animals otherwise displayed unchanged
morphological and functional conditions.
Post-mortem assessment and clinical pathology
Post-mortem epicardial inspection confirmed the intra-
operative findings for all animals (n = 9). There was no
evidence of structural impact, tissue damage, vessel im-
pingement, bleeding or hematoma at the sites of delivery
tool jaw clamping/closure (without fastener deployment)
(n = 18), at the ostial sites of fastener deployment (n =
18), or at the sites of “rapid deployment” on the LAA/
RAA body (n = 2). For all ostial deployments except one
(n = 17/18, see above), the device was well positioned at
the ostium, conformed to the surrounding cardiac struc-
tures and had a sufficient length to fully traverse the ap-
pendage (Fig. 6a-b). Consistent with the intraoperative
observations, complete engagement of all connector
pairs was confirmed in nineteen of twenty deployed fas-
teners. One of twenty fasteners exhibited incomplete en-
gagement of one connector pair (the most distal one), as
Fig. 3 a-f Appendage access with delivery tool and fastener safety assessment. Jaw closure on LAA (left) and RAA (right) (a and b). Safety
assessment of LAA (left) and RAA (right) immediately (c and d) and≥ 5 min (e and f) after jaw reopening and removal. Location of jaw closure is
marked with purple surgical ink
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previously observed in vivo; complete closure of the
LAA was confirmed for this deployment.
Endocardial inspection confirmed for all specimens
that there was no communication between the atrium
and the appendage, indicating complete closure in all
cases. The device-enabled appendage occlusion created a
nearly smooth line of closure via symmetric endocardial
tissue coaptation. In one animal, two locations of pin-
point congestion were noted on the endocardial surface
of the RA adjacent to the deployed fastener; however,
this observation was not judged to be related to the fas-
tener but may have eventually occurred during RAA ex-
posure and the various (re-)positioning and re-opening
maneuvers. No other evidence of adverse impact was
seen at the location of fastener deployment or at adja-
cent tissue structures.
Tissue thickness measurements indicated that the ap-
pendage tissues at the location of delivery tool jaw
clamping/closure (without fastener deployment) and im-
mediately adjacent to the deployed fastener at the LAA
and RAA ostia ranged from approximately 1.5–7.8 mm
and 1.5–6.8 mm on the LAA and RAA respectively.
Discussion
TPP device enables safe and efficacious appendage
closure
We evaluated the in vivo performance of the new TigerPaw
Pro (TPP) device for epicardial LAAO in a translational ca-
nine model. Our results demonstrate a good safety and effi-
cacy profile of the device. All deployment procedures could
be performed successfully and, importantly, no instances of
device-related intra-procedural or post-procedural complica-
tions were observed (i.e., bleeding, tearing, other tissue dam-
age, device migration, vessel impingement), substantiating
the overall safety of the procedure and suggesting that the is-
sues of the previously recalled TigerPaw System II have been
resolved by redesign.
In all cases, complete closure of the appendage was
achieved, as validated by ICE, visual inspection and post-
mortem evaluation. The examinations showed that a
smooth endocardial surface was achieved (via symmetric
tissue coaptation) after fastener deployment, which re-
duces the potential risk of blood-stasis and thrombus
formation at the closed ostium, and thus represents an
important criterion in appendage occlusion [4].
Fig. 4 a-f Delivery tool positioning, deployment, removal, and post-deployment epicardial assessment. Jaw closure on LAA ostium/neck (left) and
RAA ostium/neck (right), in preparation for fastener deployment (a and b). Post-deployment assessment of LAA (left) and RAA (right) immediately
(c and d) and≥ 5 min (e and f) after fastener deployment
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TPP device offers good usability, the ability for re-
positioning and rapid delivery
The device was extensively tested for its ability to apply
the fastener to the appendage (procedural feasibility) and
for its intra-procedural ease of use (usability). The device
demonstrated a good performance profile, as all testing
maneuvers could be safely and precisely performed. In
all attempts, after closing and clamping the device jaws
on appendage tissue, the jaws could be reopened without
issue and without inadvertently initiating fastener de-
ployment. For all fastener applications, access, position-
ing and deployment at the ostium was safe, rapid, and
accurate. In four applications, after clamping tissue but
prior to initiating fastener deployment, the operators de-
cided to reopen the jaws to achieve better positioning at
the ostium; this maneuver was completed uneventfully,
indicating that the device allows for safe and reliable
reopening and repositioning, if deemed necessary. Con-
sidering the different morphologies the LAA can present
with [12], the ability for fast and safe device reposi-
tioning represents an important feature for achieving ef-
ficient LAAO. Notably, two attempts of a rapid,
uninterrupted delivery procedure were successful, pro-
viding further evidence of the device’s ability to be de-
ployed quickly.
Two difficulties were encountered during testing; one
instance of an unengaged fastener connector pair, and
one instance of residual LAA stump. The unengaged
connector pair was attributed to unintended capture of
pericardial tissue in the jaws during positioning; this
situation was likely induced by the use of the larger (45
mm) fastener in the small thoracic space of the canine
model. The one instance of LAA residual stump was also
related to maneuverability of the larger fastener in the
Fig. 5 a-c Post-deployment endocardial assessment. Left-coronary angiography demonstrating patent coronary arteries with two fasteners
deployed on the LAA and RAA (green dotted lines) (a). Intra-cardiac echo showing the LA and the open LAA pre-deployment (b) and the
occluded LAA post-deployment of the fastener (c)
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canine chest, and was attributed by the operator to the
space constraints of the model. Retrospectively, the
smaller (35 mm) device may have avoided both difficul-
ties highlighting the importance of appropriate sizing
when targeting the space-limited and fragile appendage
environment. Notably, in none of these various maneu-
vers and device deployments did any technical issues or
complications occur, such as tissue damage or tearing,
bleeding or device dislodgement, indicating an encour-
aging usability and safety profile of the device.
Evidence of epicardial device enabled LAAO
Mechanical occlusion of the LAA (using either surgical
or interventional approaches) has been repeatedly sug-
gested as a potential alternative to OAC therapy in pa-
tients with AF, and is currently under intense evaluation
[4]. To date, only for interventional devices (e.g., Watch-
man, Boston Scientific, Marlborough, MA, USA) has a
reasonable efficacy been demonstrated in prospective
randomized clinical trials [6, 13]; the outcomes for surgi-
cal techniques still remain heterogeneous, and so far,
data from clinical trials remain scarce [4]. In particular,
durability and completeness of LAA closure still repre-
sent major issues for most surgical approaches, thus lim-
iting the overall therapy efficacy [4]. In this regard,
device-enabled epicardial approaches have been repeat-
edly suggested as a potential option to achieve safe,
complete and durable occlusion of the LAA [8]. Notably,
10 years after its introduction and with currently >
200.000 devices sold, the AtriClip device possesses the
largest body of clinical experience for device-enabled
surgical approaches. Initial results from a prospective
European clinical pilot trial and a US-based multicenter
trial (EXCLUDE) showed a good safety and efficacy pro-
file for the AtriClip device using systematic imaging in
controlled follow-up at 3 months [7, 14]. These data
were further validated by computed tomography in con-
trolled mid- and long-term studies demonstrating safe,
durable and complete LAA occlusion [9, 15, 16], as well
as initial signs of potential reduction of stroke risk in pa-
tients with discontinued OAC [8]. A recent systematic
review on outcomes of LAA occlusion using the AtriClip
device showed the device to be safe and effective in the
management of patients with atrial fibrillation, either as
an adjunct in patients undergoing cardiac surgery or as a
stand-alone thoracoscopic procedure with successful
LAA occlusion in 97.8% of patients and no reported
device-related adverse events [17].
In 2009, the TigerPaw System (TigerPaw) epicardial
LAA occlusion system (LAAx, Inc., Livermore, CA, now
Getinge AB, Sweden) was evaluated in a prospective
multicenter trial including sixty patients [10], demon-
strating short-term outcomes comparable to the AtriClip
studies [7, 14]. In all patients, the TigerPaw device could
Fig. 6 a-b Post-deployment necropsy assessment. Representative necropsy images of the LAA (a) and RAA (b) demonstrating a complete LAA
closure after faster deployment
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be safely and rapidly implanted (< 30 s). Trans-
esophageal echocardiography immediately after delivery
and at 3 months follow-up confirmed the absence of any
leaks, indicating complete and durable LAA occlusion
and further validating the concept of device enabled
epicardial LAA closure [10]. However, despite these en-
couraging initial experiences, the next-generation Tiger-
Paw System II was voluntarily recalled in 2015 due to
the increased occurrence of intra-procedural technical
problems and related safety issues [11]. In order to ad-
dress these issues, the TigerPaw II system underwent
systematic redesign with a particular focus on improving
performance of the delivery tool in the device deploy-
ment procedure. Hence, the data presented here are of
high relevance as they provide the first in vivo experi-
ence with the new TigerPaw Pro design, and may there-
fore build the basis for further clinical use.
The field of surgical LAA closure remains an import-
ant scientific topic, as despite accumulating preliminary
evidence [18] and ongoing trial effort (LAAOS III), ro-
bust clinical data supporting the efficacy of surgical LAA
closure are still scarce. Consequently, current guidelines
limit surgical LAA closure to a Class IIb, Level of Evi-
dence B recommendation during open-heart procedures
[3]. The experience drawn from this study, along with
the experiences from a similar device, the AtriClip, need
to be translated into a well-designed clinical trial to pro-
vide the long-needed robust evidence for epicardial
device-enabled surgical LAA closure. With the still-
unknown clinical implications of issues with percutan-
eous devices, a collaborative effort of both cardiac sur-
geons and cardiologists in the setting of a Heart Team is
of utmost importance, in order to present patients with
tailored therapies.
Our study has several limitations: First, this was an
acute study, with no long-term follow-up in regard to
safety and durability of appendage closure. Our protocol
focused on detailed assessment of intra-procedural safety
and device usability after its re-design, since these were
the primary issues of the previous TigerPaw System II. It
must be noted that epicardial LAAO with AtriClip or
TigerPaw II have been demonstrated to remain durable
during follow-up when complete closure was docu-
mented at the time of implantation [4].
Second, all testing was conducted in a preclinical ani-
mal model, with a limited number of surgeons and of
TPP device used, which necessarily cannot represent the
full range of conditions (i.e. appendage size and morph-
ology, type and history of arrhythmia, tissue fragility,
etc.) and operator experiences to be expected in actual
clinical use. Third, all animals were fully heparinized
after sternotomy in order to achieve a coagulation status
as in routine cardiac surgery. Due to the acute nature of
this study with still active full heparinization at the time
of euthanasia, any clot formation along the closure
line was unlikely and thus not observed. However, the
absence of any bleeding complication or relevant
hematoma at the site of application despite full
heparinization further supports the safety profile of
the device.
Conclusions
The new TPP device for epicardial LAAO demonstrated
safety and efficacy in a preclinical canine model. All de-
ployment procedures were performed safely and success-
fully, and achieved complete LAAO. The device showed
good ease of use with respect to LAA access, the ability
for re-positioning (after engagement) and rapid deploy-
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